GVS S.p.A. is a manufacturer of filtration solutions for the healthcare, life sciences, energy, mobility, and health and safety sectors. Founded in 1979, the company operates through four main divisions: Healthcare & Life Sciences, Energy & Mobility, Health & Safety, and Transfusion Medicine. Its product portfolio includes blood filters, infusion devices, stopcocks, microfiltration technologies for bioprocessing and diagnostics, automotive filtration components, and personal protective equipment. The group serves global markets with manufacturing plants in Italy, the United Kingdom, Brazil, the United States, China, Mexico, Romania, and Puerto Rico, alongside commercial offices worldwide. Key subsidiaries and acquired entities include Valplast, RPB, Shanghai Transfusion Technology, Haemotronic, and Haemonetics’ Whole Blood business. GVS listed on the Italian Stock Exchange in 2020.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Medical Instruments & Supplies Homepage gvs.com
Sector Healthcare IR page gvs.com/en
Tags
blood filtration, infusion devices, microfiltration, automotive filtration, personal protective equipment, transfusion medicine, bioprocessing, pharmaceutical packaging, Valplast, RPB, Shanghai Transfusion Technology, Haemotronic, Haemonetics, GVS MedTech
Press page gvs.com/en/news

Metrics

Valuation  
Market cap € 819.829M
Market cap (USD) $ 919.357M
P/E 44.48
PEG —
P/BV 1.88
P/S 1.89
P/OCF 10.95
P/FCF 39.46
Dividend yield —
Turnover / mcap —
Returns  
ROE 4.1%
ROI 5.0%
ROIC 5.0%
Profit margin 4.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -8.5%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 60
Quality score -41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 433.189M 436.357M 432.357M 392.033M 343.075M 365.212M
Net profit 18.414M 33.375M 13.642M 24.12M 67.604M 78.083M
Free cash flow 20.778M 67.928M 80.255M 58.28M 36.043M 86.767M

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) 52.1M 53M 72.9M 54.1M 55.4M 50.8M
↳ YoY growth +1.7% +37.7% -25.8% +2.3% -8.3%
↳ 5y CAGR -0.5%
Lease liabilities (EUR) 8.97M 11.5M 25.2M 20.5M 22.2M 22.3M
Cash and deposits (EUR) 125M 137M 135M 191M 103M 78.7M
Intangible assets (EUR) — — — 472M 473M 434M
Right-of-use assets (EUR) 8.44M 10.4M 23M 20.2M 23.4M 25.2M
Cash flow detail
Operating cash flow (EUR) 114M 55.5M 76.1M 102M 97.1M 74.9M
Purchases of property, plant and equipment (EUR) -27.3M -19.4M -17.8M -21.3M -29.2M -54.1M
Purchases of intangible assets (EUR) -4.06M -3.76M -5.02M -6.86M -8.15M -9.51M
Change in receivables (cash effect) (EUR) -6.17M -4.67M -11.9M 19.2M -1.2M -1.56M
Change in inventories (cash effect) (EUR) -21M -9.53M 3.14M 14.6M 3.19M -13.4M
Change in payables (cash effect) (EUR) 18.2M -6.41M 13.8M -17.4M 4.82M 7.22M
Dividends paid (cash effect) (EUR) -1.68M -22.7M 0.00 — — —
Interest paid (cash effect) (EUR) -4.96M -2.94M -4.9M -17.9M -18.2M -12.4M
Income taxes paid (cash effect) (EUR) -16.3M -32.6M 9.85M 10.5M 15M 14.5M
Operating cash flow before change in receivables (EUR) 120M 60.2M 88M 82.4M 98.3M 76.5M
Free cash flow (OCF - PPE - intangibles) (EUR) 82.7M 32.3M 53.3M 73.4M 59.8M 11.3M
Income detail
Total comprehensive income (EUR) 69.3M 76.2M 31.7M 5.23M 39.9M -6.64M
Comprehensive income to owners (EUR) 69.3M 76.1M 31.7M 5.28M 39.9M -6.6M
Provision for credit losses (EUR) 335,000 462,000 506,000 594,000 696,000 240,000
Credit cost ratio (credit losses / average receivables) (%) — 0.9% 0.8% 0.9% 1.3% 0.5%
Reported May 30, 2023 May 30, 2023 May 30, 2023 Apr 23, 2025 Apr 23, 2025 Apr 29, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

aabb

  1. Home page

  2. News & Media

  3. GVS Transfusion Medicine to Exhibit at the AABB Annual Meeting 2026

Share

2026/10/08

GVS will once again participate in the AABB Annual Meeting, one of the most important international events dedicated to blood banking, transfusion medicine and biotherapies, taking place in Atlanta, Georgia, from October 17 to 19, 2026. The event brings together healthcare professionals, researchers, industry leaders and decision-makers from around the world to explore the latest developments shaping the future of the sector.

During the exhibition, the GVS Transfusion Medicine team will be available to meet customers, partners and industry professionals, presenting the company's comprehensive portfolio of filtration and blood management solutions designed to support safety, efficiency and performance across transfusion workflows.

The AABB Annual Meeting  represents a key opportunity to engage with the global transfusion medicine community, exchange knowledge and discuss emerging challenges and trends affecting blood collection, processing and patient care. The 2026 edition will feature educational sessions, scientific presentations and networking opportunities focused on the latest advances in blood banking, transfusion medicine and biotherapies.

As a long-standing partner to healthcare institutions and blood centers worldwide, GVS remains committed to supporting innovation and advancing technologies that contribute to safer and more efficient transfusion practices.

We look forward to welcoming visitors at our booth and discussing how GVS solutions can help address the evolving needs of the transfusion medicine field.

AABB Annual Meeting 2026
October 17-19, 2026
Georgia World Congress Center, Atlanta, Georgia (USA)

Share

Related articles

  1. World Blood Donor Day 2026: One Drop of Humanity

    Transfusion Medicine donorday Find out more

  2. GVS at ISBT 2026: Integrated Solutions for Collection, Processing and Transfusion

    Transfusion Medicine isbt Find out more

  3. Covina: a Strategic Hub for GVS Transfusion Medicine

    Transfusion Medicine Strategic Hub Find out more

  4. SQ40: High Flow Blood Filtration Designed for Performance in Transfusion Medicine

    Transfusion Medicine sq40 Find out more

GVS S.p.a. logo

Copyright 2022 GVS S.p.A. VAT n. 00644831208

Go back to the global website Select a country or territory to show the localized content:

Continue

To access the localized content, select the website associated with the Division of your interest:

MedTech

Transfusion Medicine

Life Sciences

Safety

Energy & Mobility

Go back to the global website

Type your search text here

Search

GVS S.p.a. logo

Via Roma, 50 - 40069 Zola Predosa (Bologna) - Italy
Tel. +39 051 6176311 | Fax +39 051 6176200 | e-mail: [email protected]

Cap. Soc. € 1.750.000,00 interamente versato | C.F. 03636630372
R.E.A 0305386/BO | Reg. Imprese 45539/BO | Mecc. BO 012048

Prompts

GVS S.p.A. (ticker GVS), listed in Italy.

ETFs Holding GVS S.p.A.

ETF Weight in ETF Shares Market value As of
AVDS 0.01% 6,208 $ 40.989K Nov 16, 2026
DFIS 0.01% 56,528 $ 391.604K Nov 12, 2026
DXIV 0.01% 2,052 $ 14.215K Nov 12, 2026
DFIC 0.00% 32,162 $ 222.806K Nov 12, 2026
DFAX 0.00% 23,527 $ 162.986K Nov 12, 2026
DFAI 0.00% 17,556 $ 121.621K Nov 12, 2026
DISV 0.00% 2,481 $ 17.187K Nov 12, 2026